Cargando…

ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis

PURPOSE: Limited effective treatments are currently available for central nervous system (CNS) metastasis (CM). This is largely driven by the inability of current therapeutics to penetrate the blood brain barrier (BBB) and the lack of preclinical models for testing new therapies. Here we study the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tew, Ben Yi, Kalfa, Alex J., Yang, Zeyi, Hurth, Kyle M., Simon, Thomas, Abnoosian, Eric, Durant, Stephen T., Hamerlik, Petra, Salhia, Bodour
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Translational Cancer Mechanisms and Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618650/ https://www.ncbi.nlm.nih.gov/pubmed/37585496 http://dx.doi.org/10.1158/1078-0432.CCR-23-0290

Ejemplares similares

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models
por: Durant, Stephen T., et al.
Publicado: (2018)

ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
por: Vokes, Natalie I., et al.
Publicado: (2023)

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
por: Illuzzi, Giuditta, et al.
Publicado: (2022)

Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
por: Nakamura, Kyoko, et al.
Publicado: (2021)

Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
por: Rodriguez-Berriguete, Gonzalo, et al.
Publicado: (2023)

Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
por: Von Roemeling, Christina A., et al.
Publicado: (2023)

Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
por: Leclercq-Cohen, Gabrielle, et al.
Publicado: (2023)

Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
por: Sperger, Jamie M., et al.
Publicado: (2023)

Ovarian Cancer–Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
por: Schouten, Philip C., et al.
Publicado: (2021)

The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
por: Cheng, Zhao, et al.
Publicado: (2022)

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
por: Xia, Youli, et al.
Publicado: (2022)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer
por: Tang, Zhe, et al.
Publicado: (2021)

Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy
por: Levin, Noam, et al.
Publicado: (2021)

Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia
por: Ding, Yang-Yang, et al.
Publicado: (2021)

Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming
por: Simonetta, Federico, et al.
Publicado: (2021)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Memory-like Differentiation Enhances NK Cell Responses to Melanoma
por: Marin, Nancy D., et al.
Publicado: (2021)

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
por: Koh, Siang-Boon, et al.
Publicado: (2021)

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
por: Kim, Dae-Hwan, et al.
Publicado: (2021)

Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer
por: Miao, Yu Rebecca, et al.
Publicado: (2021)

Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER(+) Breast Cancer
por: Servetto, Alberto, et al.
Publicado: (2021)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

IL13Rα2 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases
por: Márquez-Ortiz, R. Alejandro, et al.
Publicado: (2021)

TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas
por: Gonzalez-Buendia, Edgar, et al.
Publicado: (2021)

DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
por: Venugopal, Kartika, et al.
Publicado: (2022)

Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
por: Carter, Jodi M., et al.
Publicado: (2021)

Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer
por: Seeber, Andreas, et al.
Publicado: (2022)

Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
por: Palmer, Adam C., et al.
Publicado: (2022)

Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception
por: Hernandez, Sharia, et al.
Publicado: (2022)

Opening of the Blood–Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models
por: Sabbagh, Aria, et al.
Publicado: (2021)

Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
por: Hashimoto, Ayumi, et al.
Publicado: (2021)

Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma
por: Zhai, Lijie, et al.
Publicado: (2021)

Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer
por: Peng, Hui, et al.
Publicado: (2021)

The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma
por: Sharma, Neeraj, et al.
Publicado: (2021)

Targeting Podoplanin for the Treatment of Osteosarcoma
por: Takemoto, Ai, et al.
Publicado: (2022)

Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
por: Vesely, Clare, et al.
Publicado: (2022)

Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations
por: Shi, Qiong, et al.
Publicado: (2022)

Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer
por: Sheehan, Beshara, et al.
Publicado: (2022)

DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
por: Kurani, Hetakshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h5u2i5nflepph41jq10re920e3